[STRATEGIC] Biopharma
· Immunology / Autoimmune · T
Cell Engager Therapies — ANNOUNCED March 23, 2026 — Expected Close Q2
2026
Gilead Agrees to Acquire Ouro Medicines for
Up to $2.175B, Betting on a T Cell "Immune Reset" for Autoimmune
Disease
Gilead's second billion-dollar immunology bet in a single month:
after closing the $7.8B Arcellx acquisition for leukemia cell therapy, Foster
City's antiviral giant agrees to pay $1.675B upfront for a Swiss-founded
startup that has developed a first-in-class T cell engager antibody for
autoimmune blood disorders — sharing the cost 50/50 with Belgian partner
Galapagos NV.
DEAL SNAPSHOT
|
UPFRONT CASH $1.675 Billion |
ANNOUNCED March 23, 2026 |
|
CONTINGENT MILESTONES Up to $500 Million |
EXPECTED CLOSE Q2 2026 (pending HSR
clearance) |
|
TOTAL POTENTIAL VALUE $2.175 Billion |
COST-SHARE Galapagos NV pays 50% of
upfront + milestones |
THE PARTIES
|
ACQUIRER Gilead Sciences, Inc.
(Nasdaq: GILD) Foster City,
CA-based global biopharmaceutical company. CEO Daniel O'Day. FY2025 revenues
~$28B, primarily driven by HIV treatments (Biktarvy, Descovy, Sunlenca) and
Veklury (remdesivir). Gilead has been aggressively rebalancing its portfolio
from pure virology toward oncology and immunology — spending ~$7.8B on
Arcellx (CLL cell therapy) earlier in March and now $1.675B+ on Ouro. The
company is in advanced discussions with Belgian biotech partner Galapagos NV
(in which Gilead already holds a significant stake) to share costs equally. |
TARGET Ouro Medicines Privately held
biotechnology company. Lead asset: OM336 — an investigational BCMAxCD3
bispecific T cell engager (TCE) antibody for autoimmune diseases,
specifically targeting conditions driven by pathogenic autoantibodies
(abnormal B cells/plasma cells that produce antibodies attacking the body's
own tissues). OM336 has received FDA Orphan Drug Designation and Fast Track
Designation for certain autoimmune diseases. Expected to enter registrational
studies in 2027. Backed by undisclosed venture investors. |
DEAL OVERVIEW & THE GALAPAGOS
CO-INVESTMENT
Gilead agreed to
acquire all outstanding equity of Ouro Medicines for $1.675 billion in upfront
cash at closing, plus up to $500 million in contingent milestone payments. In
an unusual and strategically elegant financing structure, Gilead is
simultaneously pursuing an agreement with Galapagos NV under which Galapagos
would pay 50% of the upfront consideration and 50% of any milestone payments —
effectively reducing Gilead's net outlay to approximately $838 million upfront.
Under the
proposed Gilead-Galapagos collaboration, Galapagos would absorb substantially
all of Ouro's operating assets and retain its employees. Galapagos would assume
responsibility for developing OM336 through the start of registrational studies
capable of supporting regulatory submissions; late-stage clinical development
costs beyond that point would be split equally between the partners. This
structure repositions Galapagos — which had undergone significant restructuring
— with a meaningful clinical-stage program and a clear development role.
"OM336 represents a potential first-in-class approach to
achieving an immune reset in patients suffering from debilitating autoimmune
diseases. This acquisition deepens our immunology pipeline and reflects our
confidence in T cell engager technology as a platform for treating serious
disease."
— Daniel O'Day,
Chairman & CEO, Gilead Sciences
THE SCIENCE: WHY T CELL ENGAGERS FOR
AUTOIMMUNE DISEASE
Autoimmune
cytopenias and other autoantibody-driven diseases — conditions where the immune
system attacks the body's own blood cells or tissues — have been treated for
decades with blunt immunosuppressants (steroids, rituximab). T cell engagers
like OM336 represent a fundamentally different approach: they recruit cytotoxic
T cells (the immune system's precision killers) to eliminate the specific B
cells and plasma cells producing the pathogenic autoantibodies, without broadly
suppressing immunity. This could enable a durable "immune reset" —
remission without indefinite immunosuppression.
The T cell
engager modality has already revolutionized blood cancer (blinatumomab for ALL,
elranatamab for myeloma). Its application to autoimmune disease is in early
stages, but the mechanistic logic is compelling. OM336's Fast Track and Orphan
Drug designations indicate the FDA views the asset as addressing a serious
unmet need.
ADVISORS
Buy-side
Financial (Gilead): Centerview
Partners LLC + TD Cowen
Buy-side
Legal (Gilead): Covington &
Burling LLP + Mayer Brown LLP + Arnold & Porter Kaye Scholer LLP
Sell-side
Financial (Ouro Medicines): Goldman
Sachs & Co. LLC (exclusive)
Sell-side
Legal (Ouro Medicines): Goodwin
Procter LLP
Galapagos
Advisor (Financial): Morgan Stanley
& Co. LLC
Galapagos
Legal: Paul Weiss LLP + Linklaters
LLP